|
|
Blood, 15 June 2007, Vol. 109, No. 12, pp. 5151-5156.
Prepublished online as a Blood First Edition Paper on March 9, 2007; DOI 10.1182/blood-2006-09-046144.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
Jean-Luc Harousseau1,
Jeffrey E. Lancet2,
Josy Reiffers3,
Bob Lowenberg4,
Xavier Thomas5,
Francoise Huguet6,
Pierre Fenaux7,
Steven Zhang8,
Wayne Rackoff8,
Peter De Porre8,
Richard Stone9, for the Farnesyltransferase Inhibition Global Human Trials (FIGHT) Acute Myeloid Leukemia Study Group
1 From the Service d'Hématologie, Hôtel Dieu, Nantes, France;
2 H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa;
3 Service des Maladies du Sang, Hôpital du Haut Leveque, Pessac, France;
4 Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands;
5 Service des Maladies du Sang, Hôpital Edouard Herriot, Lyon, France;
6 Service d'Hématologie, Chu Purpan, Toulouse Cedex, France;
7 Hématologie, Avicenne Hôpital, Paris, France;
8 Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ; and
9 Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA
This phase 2 study evaluated the efficacy and safety of the oral farnesyltransferase inhibitor tipifarnib in adults with refractory or relapsed acute myeloid leukemia (AML). Patients (n = 252) received tipifarnib 600 mg twice a day for 21 days in 28-day cycles. Median age was 62 years; 99 (39%) patients were 65 years or older. Eleven (4%) of 252 patients achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp; 9 CR and 2 CRp). Nineteen patients (8%), including those who achieved CR/CRp, achieved a reduction in bone marrow blasts to less than 5% blasts. Bone marrow blasts were reduced more than 50% in an additional 8 patients (total = 27; 11%). Median survival was 369 days for patients who achieved CR/CRp. Myelosuppression was the most common adverse event. The most common nonhematologic toxicities were fever, nausea, and hypokalemia. Single-agent treatment with tipifarnib induced durable CR/CRp, which was associated with prolonged survival, in some patients with refractory or relapsed AML. The response rate observed in this heavily pretreated group of patients suggests the requirement to enhance the response rate either by combining tipifarnib with other active agents or determining factors that are predictive of response.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. van der Weide, S. D.P.W.M. de Jonge-Peeters, F. Kuipers, E. G.E. de Vries, and E. Vellenga
Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples
Clin. Cancer Res.,
May 1, 2009;
15(9):
3076 - 3083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Laubach and A. V. Rao
Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly
Oncologist,
October 1, 2008;
13(10):
1097 - 1108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Haferlach
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
Hematology,
January 1, 2008;
2008(1):
400 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone
Genetically Defined Prognostic Factors and Novel Therapeutics for AML
ASCO Educational Book,
January 1, 2008;
2008(1):
280 - 284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J.L. Kaspers and C. M. Zwaan
Pediatric acute myeloid leukemia: towards high-quality cure of all patients
Haematologica,
November 1, 2007;
92(11):
1519 - 1532.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
